UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000035764
Receipt number R000040702
Scientific Title The prognosis of patients with recurrent or persistent ovarian clear cell carcinoma: Results from a randomized phase III study (JGOG3017/GCIG)
Date of disclosure of the study information 2019/02/04
Last modified on 2020/08/06 11:34:37

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The prognosis of patients with recurrent or persistent ovarian clear cell carcinoma: Results from a randomized phase III study (JGOG3017/GCIG)

Acronym

JGOG 3017A1

Scientific Title

The prognosis of patients with recurrent or persistent ovarian clear cell carcinoma: Results from a randomized phase III study (JGOG3017/GCIG)

Scientific Title:Acronym

JGOG 3017A1

Region

Japan


Condition

Condition

recurrent or persistent ovarian clear cell carcinoma

Classification by specialty

Obstetrics and Gynecology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

This study aimed to clarify PPS in recurrent or persistent CCC confirmed by CPR.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The primary endpoint was to examine PPS of patients with recurrent CCC.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

81 years-old >

Gender

Female

Key inclusion criteria

The JGOG3017/GCIG Trial was the randomized phase 3 study to compare paclitaxel plus carboplatin (TC) versus CPT-11 plus cisplatin (CPT-P) for 667 patients with stage 1 to 4 CCC. However, forty-three patients (6.4%) were ineligible due to non CCC histology, four withdrew from the study, and one was duplicated. A total of 619 patients with CCC were eligible for inclusion.
Among 619 patients with CCC, 166 patients, excluding dead of disease without recurrence, had recurrent or persistent CCC.

Key exclusion criteria

However, forty-three patients (6.4%) were ineligible due to non CCC histology, four withdrew from the study, and one was duplicated.

Target sample size

166


Research contact person

Name of lead principal investigator

1st name Tsutomu
Middle name
Last name Tabata

Organization

Mie university hospital

Division name

Obstetrics and Gynecology

Zip code

514-8507

Address

2-174 Edobashi, Tsu city, 514-8507, Japan

TEL

0592230737

Email

tabatat@clin.medic.mie-u.ac.jp


Public contact

Name of contact person

1st name Eiji
Middle name
Last name Kondo

Organization

Mie university hospital

Division name

Obstetrics and Gynecology

Zip code

514-8507

Address

2-174 Edobashi, Tsu city, 514-8507, Japan

TEL

0592230737

Homepage URL


Email

eijikon@clin.medic.mie-u.ac.jp


Sponsor or person

Institute

JGOG

Institute

Department

Personal name



Funding Source

Organization

JGOG

Organization

Division

Category of Funding Organization

Outside Japan

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Mie university hospital

Address

2-174, Edobashi, Tsu, Mie

Tel

059-232-1111

Email

eijikon@clin.medic.mie-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 02 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 06 Month 22 Day

Date of IRB

2018 Year 01 Month 10 Day

Anticipated trial start date

2018 Year 06 Month 22 Day

Last follow-up date

2019 Year 08 Month 06 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded

2020 Year 02 Month 20 Day


Other

Other related information

Multicenter Trial


Management information

Registered date

2019 Year 02 Month 04 Day

Last modified on

2020 Year 08 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040702


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name